AtlasXomics

Executive Summary

AtlasXomics is a privately held biotech company based in New Haven, CT, focused on advancing epigenomic research through innovative spatial epigenetic assays. Founded in 2017, the company offers a proprietary kit enabling spatial-ATAC-seq and CUT&Tag tools, allowing researchers to map chromatin accessibility and histone modifications at single-cell resolution within intact tissue sections. This technology addresses a critical gap in understanding gene regulation in heterogeneous tissues, enabling deeper insights into development, disease progression, and therapeutic responses. By providing a ready-to-use, high-resolution spatial epigenomics solution, AtlasXomics accelerates discovery in fields like oncology, neuroscience, and immunology, where tissue architecture and epigenetic states are key. The company targets the growing market for spatial multi-omics, which is projected to expand rapidly as researchers seek to combine transcriptomics, proteomics, and epigenomics in a spatial context. With its unique product and early-mover advantage in spatial epigenomics, AtlasXomics is poised to become an essential tool provider for academic and pharmaceutical R&D.

Upcoming Catalysts (preview)

• Q4 2026Launch of upgraded spatial multi-omics kit with enhanced throughput or compatibility60% success
• Q2 2026Key partnership with major pharmaceutical company for drug discovery programs40% success
• Q3 2026Series A funding round to expand commercial operations50% success